Chronic Phase Chronic Myelogenous Leukemia Completed Phase 1 / 2 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028870 (Chronic Phase Chronic Myelogenous Leukemia)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004918Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeTreatment